IPSC vs. ADVM, IPHA, KOD, CMPX, INMB, ABOS, ZURA, MGX, OPT, and AGEN
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Adverum Biotechnologies (ADVM), Innate Pharma (IPHA), Kodiak Sciences (KOD), Compass Therapeutics (CMPX), INmune Bio (INMB), Acumen Pharmaceuticals (ABOS), Zura Bio (ZURA), Metagenomi (MGX), Opthea (OPT), and Agenus (AGEN). These companies are all part of the "biological products, except diagnostic" industry.
Century Therapeutics (NASDAQ:IPSC) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
Century Therapeutics presently has a consensus target price of $13.20, suggesting a potential upside of 327.18%. Adverum Biotechnologies has a consensus target price of $29.00, suggesting a potential upside of 231.43%. Given Century Therapeutics' higher possible upside, equities research analysts plainly believe Century Therapeutics is more favorable than Adverum Biotechnologies.
50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 7.6% of Century Therapeutics shares are held by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Adverum Biotechnologies has a net margin of 0.00% compared to Century Therapeutics' net margin of -9,742.41%. Century Therapeutics' return on equity of -59.74% beat Adverum Biotechnologies' return on equity.
In the previous week, Century Therapeutics and Century Therapeutics both had 16 articles in the media. Century Therapeutics' average media sentiment score of 0.83 beat Adverum Biotechnologies' score of 0.15 indicating that Century Therapeutics is being referred to more favorably in the media.
Adverum Biotechnologies has higher revenue and earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Adverum Biotechnologies received 336 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 60.97% of users gave Adverum Biotechnologies an outperform vote while only 60.87% of users gave Century Therapeutics an outperform vote.
Century Therapeutics has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
Summary
Century Therapeutics beats Adverum Biotechnologies on 9 of the 16 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
